Corcept Reports 7.2 Months of Progression-Free Survival in Ovarian Cancer Trial
Key Facts
Corcept reported results from Part A of the Bella trial, with median progression-free survival of 7.2 months among patients with platinum-resistant ovarian cancer who received relacorilant with nab-paclitaxel and bevacizumab. The objective response rate was 59% in the interim analysis, according to results reported by Reuters via Investing.com. The trial included 95 patients, whose enrollment was completed in December 2025, according to the company’s filing with the U.S. Securities and Exchange Commission. The triplet regimen remains under study; Lifyorli has not been approved for use with bevacizumab. The figures offer an initial read on efficacy, while median overall survival had not been reached at the time of the analysis.
The results comparison included data from the separate Phase 3 ROSELLA trial, which studied Lifyorli with nab-paclitaxel without bevacizumab, alongside chemotherapy alone. In the comparison cited with the Bella results, median progression-free survival was 5.4 months with the doublet and 3.9 months with nab-paclitaxel alone, compared with 7.2 months in Bella. The objective response rate in ROSELLA was 37% with the doublet and 30% with single-agent treatment, compared with 59% in Bella. But the figures come from two different trials, one Phase 2 and the other Phase 3, and do not represent a direct randomized comparison between arms. In ROSELLA, 381 patients were randomly assigned 1:1 between the two treatments, according to Corcept.
In the final ROSELLA analysis, Corcept said adding Lifyorli to nab-paclitaxel was associated with a 35% reduction in the risk of death compared with nab-paclitaxel alone. Median overall survival was 16.0 months with the combination, versus 11.9 months with single-agent treatment. In Bella, 88% of patients were alive at the six-month overall-survival assessment. Median overall survival had not been reached at the time of the interim analysis, so the Bella result remains a six-month assessment. These data show different outcome measures, and ROSELLA and Bella figures should not be treated as results from a single trial.
The group with no prior bevacizumab treatment, which made up about half of participants, recorded median progression-free survival of 8.1 months and an objective response rate of 66%. The survival rate in this group was 91% at the six-month mark. These figures remain subgroup results from Part A, according to data reported by Reuters via Investing.com. On safety, the company said recorded events were consistent with the known profiles of each drug in the combination, and no new safety signals were observed. The most common events, affecting at least 25% of participants, were neutropenia, anemia, nausea, asthenia, nail disorders, peripheral neuropathy, fatigue and leukopenia.
Bella began in April 2025 as an open-label Phase 2 trial comprising three parts, with progression-free survival as the primary endpoint in each part and overall survival as a key secondary endpoint. Its design differs from ROSELLA, a pivotal randomized Phase 3 trial. In the regulatory background, the U.S. Food and Drug Administration on March 25, 2026, approved relacorilant, marketed as Lifyorli, with nab-paclitaxel to treat adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. The indication covers patients who have received one to three prior lines of systemic therapy, one of which must include bevacizumab. The triplet regimen tested in Bella is not covered by that approval, and the approved prescribing information states that serious adverse reactions occurred in 35% of patients receiving the doublet.
In the market, Corcept shares, listed under the ticker CORT, closed at $85.86 on 23 October 2026, according to EL7 data. Available closing data do not include the session high or low. Bella’s results link efficacy measures with safety monitoring, while median overall survival remained immature at the interim analysis. The comparison with ROSELLA is also based on results from another trial and a different treatment regimen. The company said full results will be presented at a medical conference next year.